Introduction: Bevacizumab is a recombinant humanized monoclonal antibody against human vascular endothelial growth factor (VEGF), which inhibits angiogenesis in tumor tissues by blocking VEGF activity. The gene discussed is VEGFA; the disease is neoplasm.